山东大学学报 (医学版) ›› 2020, Vol. 58 ›› Issue (12): 117-120.doi: 10.6040/j.issn.1671-7554.0.2020.0862
高奎1,万广宁2,宋晓鹏2,信波2
中图分类号:
| [1] Eroglu Z, Tagawa T, Somlo G. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer[J]. Oncol, 2014, 19(2): 135-150. [2] Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer(CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(4): 519-530. [3] Ma F, Li Q, Chen S, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible Pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer[J]. J Clin Oncol, 2017, 35(27): 3105-3112. [4] Ma F, Ouyang QC, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study[J]. J Clin Oncol, 2019, 37(29): 2610-2619. [5] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志, 2019, 29(8): 609-680. [6] Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer[J]. Annu Rev Med, 2015, 66: 111-128. doi:10.1146/annurev-med-042513-015127. [7] Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis[J]. Oncogene, 2007, 26(45): 6469-6487. [8] Wilson FR, Coombes ME, Brezden-Masley C, et al. Herceptin®(trastuzumab)in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis[J]. Syst Rev, 2018, 7(1): 191. doi:10.1186/s13643-018-0854-y. [9] Goutsouliak K, Veeraraghavan J, Sethunath V, et al. Towards personalized treatment for early stage HER2-positive breast cancer[J]. Nat Rev Clin Oncol, 2020, 17(4): 233-250. [10] Llombart-Cussac A, Cortés J, Paré L, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer(PAMELA): an open-label, single-group, multicentre, phase 2 trial[J]. Lancet Oncol, 2017, 18(4): 545-554. [11] 宋国红, 李惠平, 邸立军, 等. 真实世界吡咯替尼治疗HER2阳性转移性乳腺癌的疗效及安全性[J]. 北京大学学报(医学版), 2020, 52(2): 254-260. SONG Guohong, LI Huiping, DI Lijun, et al. Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice[J]. Journal of Peking University(Health Sciences), 2020, 52(2): 254-260. [12] 房文通, 顾艳宏. 伴有合并症的结直肠癌治疗的药物选择[J]. 中华结直肠疾病电子杂志, 2018, 7(5): 420-430. FANG Wentong, GU Yanhong. Medication options for colorectal cancer with complications[J]. Chinese Journal of Colorectal Diseases, 2018, 7(5): 420-430. |
| [1] | 廉开礼,李炎,张娜,靳桂媛,刘素侠. TIPE3上调P-gp表达降低乳腺癌细胞对阿霉素的敏感性[J]. 山东大学学报（医学版）, 2017, 55(5): 36-42. |
| [2] | 李雁翔,张温花,杨飞龙,方量,徐忠华. 尿路上皮癌BRCA1基因与蛋白表达的相关性[J]. 山东大学学报（医学版）, 2017, 55(5): 91-94. |
| [3] | 徐志宏,刘荣凤,王晓翔,冯莉,姚铁柱,刘红. 养正消积胶囊联合化疗治疗转移性乳腺癌的临床疗效及安全性[J]. 山东大学学报（医学版）, 2016, 54(5): 79-83. |
| [4] | 刘相永,孙颖,黎莉. PARP-1抑制剂对BRCA1基因沉默的乳腺癌细胞株MCF-7及PTEN基因沉默的前列腺癌细胞株22RV1增殖的影响[J]. 山东大学学报（医学版）, 2016, 54(5): 6-11. |
| [5] | 徐志宏,姚铁柱,吴小华. 同时性原发性乳腺癌合并原发性双侧卵巢癌1例[J]. 山东大学学报（医学版）, 2016, 54(1): 94-96. |
| [6] | 李靖华, 李伟华. 乳腺纤维瘤与乳腺癌的超声鉴别诊断[J]. 山东大学学报（医学版）, 2014, 52(Z1): 142-143. |
| [7] | 曾林文, 吴鸣, 宗兵. 环磷酰胺联合多西他赛用于乳腺癌术后化疗的近期疗效观察[J]. 山东大学学报（医学版）, 2014, 52(S1): 111-111. |
| [8] | 李玲, 王丽丽, 王胜江, 于超, 刘延鹏, 徐成伟. 乳腺癌患者血浆D-二聚体水平与预后关系的探讨[J]. 山东大学学报（医学版）, 2014, 52(9): 77-80. |
| [9] | 孙颖1，丁焕1，黎晓晴2，黎莉1. 转染INPP4B基因对三阴性乳腺癌细胞株MDA-MB-231增殖的影响[J]. 山东大学学报(医学版), 2013, 51(12): 41-45. |
| [10] | 孙燕来1，宋希林2，唐鲁兵3，王斌1，张毅1. BRMS1基因对人直肠癌裸鼠成瘤性及转移能力的影响[J]. 山东大学学报(医学版), 2012, 50(9): 25-. |
| [11] | 王东秋1，高杰1，田明忠1，朱长军2. 驱动蛋白分子驱动蛋白分子Kif18A各功能域细胞定位的研究驱动蛋白分子Kif18A各功能域细胞定位的研究[J]. 山东大学学报(医学版), 2010, 48(5): 40-43. |
| [12] | 郭鲁1，胡晓燕1，蒋雅丽1，徐同福1，王品2，李铭2，张莲英1. 真核表达载体pEGFP-N1-ZIP10的构建及其对人乳腺癌细胞中其他锌转运体基因表达的影响[J]. 山东大学学报(医学版), 2010, 48(11): 29-32. |
|
||
